General principles of antiarrhythmic therapy for ventricular tachyarrhythmias

American Journal of Cardiology

Volumn 80, Issue 8 A, 1997, Pages

  Landers, Mark D ^a   Reiter, Michael J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

CARDIOVERSION; DEFIBRILLATOR; DOSE RESPONSE; HEART ARREST; HEART DEATH; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SURVIVAL;

EID: 0030827535     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00712-1     Document Type: Article

References (137)

1. Selzer A, Wray HW. Quinidine syncope paroxysmal ventricular fibrillation occurring during treatment of chronic atrial fibrillation . Circulation. 30:1964;17-26.
2. Cobb LA, Baum RS, Alvarez H, Schaffer WA. Resuscitation from out-of-hospital ventricular fibrillation four years follow-up . Circulation. 52:(suppl III):1975;223-228.
3. Myerburg RJ, Briese FW, Conde C, Mallon SM, Liberthson RR, Castellanos A. Long-term antiarrhythmic therapy in survivors of prehospital cardiac arrest initial 18 months experience . JAMA. 238:1977;2621-2624.
4. Conde C, Castellanos A, Sheps DS, Sung RJ, Briese FW, Myerburg RJ. Asymptomatic complex ventricular arrhythmiass in long-term survivors of unexpected cardiac arrest (Abstr.) . Am J Cardiol. 39:1977;276.
5. Myerburg RJ, Conde C, Sheps DS, Appel RA, Kiem I, Sung RJ, Castellanos A. Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest comparison of effects on chronic ventricular arrhythmiass and recurrent cardiac arrest . Circulation. 59:1979;855-863.
6. Myerburg RJ, Kessler KM, Estes D, Conde CA, Luceri RM, Zaman L, Kozlovskis PL, Castellanos A. Long-term survival after prehospital cardiac arrest analysis of outcome during an 8 year study . Circulation. 70:1984;538-546.
7. Moosvi AR, Goldstein S, Vanderburg-Medendorp S, Landis JR, Wolfe RA, Leighton R, Ritter G, Vasu CM, Acheson A. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. Am J Cardiol. 65:1990;1192-1197.
8. Neilsen BL, Clausen J, Nielsen JS. Can procainamide improve the prognosis of patients with ventricular arrhythmiass after myocardial infarction? Dan Med Bull. 25:1978;121.
9. Hallstrom AP, Bigger JT, Roden D, Friedman L, Akiyama T, Richardson DW, Rogers WJ, Waldo AL, Pratt CM, Capone RJ, Griffith L, Theroux PA, Barker AH, Woosley RL. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmias. J Am Coll Cardiol. 20:1992;259-264.
10. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med. 297:1977;750-757.
11. Risk stratification and survival after myocardial infarction. N Engl J Med. 309:1983;331-336.
12. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, Jaffe AS, Muller JE, Roberts R, Raabe DS, Croft CH, Passamani E, Braunwald E, Willerson JT. Risk factors for sudden death after acute myocardial infarction two year follow-up . Am J Cardiol. 54:1984;31-36.
13. Moss AJ, Davies HT, DeCamilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation. 60:1979;998-1003.
14. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmiass, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 69:1984;250-257.
15. Prognostic importance of premature beats after myocardial infarction experience in the Coronary Drug Project . JAMA. 223:1973;1116-1124.
16. Kotler MN, Tabatznik B, Mower MM, Tominga S. Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation. 47:1973;959-966.
17. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol. 52:1983;32C-36C.
18. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmiass during the year after acute myocardial infarction the CAPS . Am J Cardiol. 61:1988;501-509.
19. Lubsen J. Secondary preventive trials with antiarrhythmic agents are we asking the right question? Eur Heart J. 5:(suppl B):1984;109-111.
20. Friedman LM. Can chronic antidysrhythmic treatment prevent sudden death? Eur Heart J. 5:(suppl B):1984;99-101.
21. Morganroth J, Bigger JT, Anderson JL. Treatment of ventricular arrhythmiass by United States cardiologists a survey before the Cardiac Arrhythmia Suppression Trial results were available . Am J Cardiol. 65:1990;40-48.
22. Vlay S. How the university cardiologist treats ventricular premature beats a nationwide survey of 65 university medical centers . Am Heart J. 110:1985;904-909.
23. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmias suppression after myocardial infarction . N Engl J Med. 321:1989;406-412.
24. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
25. Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring . J Am Coll Cardiol. 10:1987;349-357.
26. Denniss AR, Richards DA, Cody DV, Russell PA, Young AA, Cooper MJ, Ross DL, Uther JB. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation. 74:1986;731-745.
27. Kuchar DL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction natural history and prognostic significance . Circulation. 74:1986;1280-1289.
28. Breithardt G, Borggrefe M. Recent advances in the identification of patients at risk of ventricular tachyarrhythmiass role of ventricular late potentials . Circulation. 75:1987;1091-1096.
29. Gomes JAC, Hariman RI, Kang PS, El-Sherif N, Chowdhry I, Lyons J. Programmed electrical stimulation in patients with high-grade ventricular ectopy electrophysiologic findings and prognosis for survival . Circulation. 70:1984;43-51.
30. Spielman SR, Greenspan AM, Kay HR, Discigel KF, Webb CR, Sokoloff NM, Rae AP, Morganroth J, Horowitz LN. Electrophysiologic testing in patients at high risk for sudden cardiac death. I. Nonsustained ventricular tachycardia and abnormal ventricular function. J Am Coll Cardiol. 6:1985;31-39.
31. Buxton AE, Marchlinski FE, Flores BT, Miller JM, Doherty JU, Josephson ME. Nonsustained ventricular tachycardia in patients with coronary artery disease role of electrophysiologic study . Circulation. 75:1987;1178-1185.
32. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiologic testing and nonsustained ventricular tachycardia use and limitations in patients with coronary artery disease and impaired ventricular function . Circulation. 82:1990;350-358.
33. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 59:1987;256-262.
34. Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death new insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction . Circulation. 78:1988;969-979.
35. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction a prospective study . Circulation. 78:1988;816-824.
36. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJJ. Clinical, angiographic, and electrophysiologic findings in patients with aborted sudden death as compared with patients with sustained ventricular tachycardia after myocardial infarction. Circulation. 71:1985;1146-1152.
37. Adhar GC, Larson LW, Brady GH, Greene HL. Sustained ventricular arrhythmiass differences between survivors of cardiac arrest and patients with recurrent sustained ventricular tachycardia . J Am Coll Cardiol. 12:1988;159-165.
38. Denniss AR, Ross DL, Richards DA, Holley LK, Cooper MJ, Johnson DC, Uther JB. Differences between patients with ventricular tachycardia and ventricular fibrillation as assessed by signal-averaged electrocardiogram, radionuclide ventriculography and cardiac mapping. J Am Coll Cardiol. 11:1988;276-283.
39. de Luna AB, Coumel P, Leclercq JF. Ambulatory sudden cardiac death mechanisms of production of fatal arrhythmias on the basis of data from 157 cases . Am Heart J. 117:1989;151-159.
40. Kempf FC, Josephson ME. Cardiac arrest recorded on ambulatory electrograms. Am J Cardiol. 53:1984;1577-1582.
41. Cobb LA, Alvarez H, Kopass MK. A rapid response system for out-of-hospital cardiac emergencies. Med Clin North Am. 60:1976;283-290.
42. Swerdlow CD, Gong G, Echt DS, Winkle RA, Griffin JC, Ross DL, Mason JW. Clinical factors predicting successful electrophysiologic-pharmacologic study in patients with ventricular tachycardia. J Am Coll Cardiol. 1:1983;409-416.
43. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmiass. N Engl J Med. 308:1983;1436-1442.
44. Pedersen DH, Zipes DP, Foster PR, Troup PJ. Ventricular tachycardia and ventricular fibrillation in a young population. Circulation. 60:1979;988-997.
45. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death structure, function, and time-dependence of risk . Circulation. 85:(suppl I):1992;I2-I10.
46. Nicod P, Gilpin E, Dittrich H, Wright M, Engler R, Rittlemeyer J, Henning H, Ross J. Late clinical outcome in patients with early ventricular fibrillation after myocardial infarction. J Am Coll Cardiol. 11:1988;464-470.
47. Volpi A, Cavalli A, Franzosi MG, Maggioni A, Mauri F. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol. 63:1989;1174-1178.
48. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 312:1985;193-197.
49. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmias. N Engl J Med. 335:1996;1933-1940.
50. Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, Simson MB, DiCarlo L, Echt DS, Packer D, et al. Prevention of sudden death in patients with coronary artery disease the Multicenter Unsustained Tachycardia Trial (MUSTT) . Prog Cardiovasc Dis. 36:1993;215-226.
51. Rosen MR, Strauss HC, Janse MJ, Roden DM, Murray KT, Stanton MS, Singh BN, Hondeghem LM, DiMarco JP, Woosley RL. Therapy: pharmacological. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: WB Saunders, 1995:1277-1347.
52. Rosen MR. Cardiac arrhythmiass and antiarrhythmic drugs recent advances in our understanding of mechanism . J Cardiovasc Electrophysiol. 6:1995;868-879.
53. Singh BN. Controlling cardiac arrhythmias overview with a historic perspective . Am J Cardiol. 80:(suppl):1997;4G-15G.
54. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olsen KH, eds. Cardiac Arrhythmias. Södertälje, Sweden: Astra, 1970:449-472.
55. Williams EM. The mode of action of quinidine on isolated rabbit atria interpreted from intracellular records. Br J Pharmacol. 13:1958;276-284.
56. Freedberg AS, Papp JG, Vaughan Williams EM. The effect of altered thyroid state on atrial intracellular potentials. J Physiol. 207:1970;357-369.
57. The 'Sicilian Gambit' a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms . Eur Heart J. 12:1991;1112-1131.
58. Schwartz PJ, Zaza A. The Sicilian Gambit revisited - theory and practice. Eur Heart J. 13:(suppl F):1992;23-29.
59. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmiass resulting from myocardial ischemia and infarction. Physiol Rev. 69:1989;1049-1069.
60. Brugada J, Boersma L, Navarro-Lopez F, Allessie M. Class III actions in an experimental model of ventricular tachycardia. Eur Heart J. 14:(suppl H):1993;50-55.
61. Josephson ME. Evaluation of antiarrhythmic agents. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2nd ed. Malvern, Pennsylvania: Lea & Febiger, 1992;630-682.
62. Spinelli W, Hoffman BF. Mechanisms of termination of reentrant atrial arrhythmiass by class I and class III antiarrhythmic agents. Circ Res. 65:1989;1565-1579.
63. Furukawa T, Rozanski JJ, Moroe K, Gosselin AJ, Lister JW. Efficacy of procainamide on ventricular tachycardia relation to prolongation of refractoriness and slowing of conduction . Am Heart J. 118:1989;702-707.
64. Gillis AM, Wyse DG, Duff HJ, Mitchell LB. Drug response at electropharmacologic study in patients with ventricular tachyarrhythmiass the importance of ventricular refractoriness . J Am Coll Cardiol. 17:1991;914-920.
65. Hohnloser SH. Proarrhythmias with class III antiarrhythmic drugs types, risks, and management . Am J Cardiol. 80:(suppl):1997;82G-89G.
66. Rinkenberger RL, Prystowsky EN, Jackman WM, Naccarelli GV, Heger JJ, Zipes DP. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies identification of drugs that exacerbate tachycardia and potential mechanisms . Am Heart J. 103:1982;177-184.
67. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects a review with special reference to torsade de pointes tachycardia . Ann Intern Med. 121:1994;529-535.
68. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion a meta-analysis of randomized control trials . Circulation. 82:1990;1106-1116.
69. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 20:1992;527-532.
70. International Mexiletine and Placebo Antiarrhythmic Coronary Trial I . Report on arrhythmias and other findings. J Am Coll Cardiol. 4:1984;1148-1163.
71. Teo KK, Yusuk S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 270:1993;1589-1595.
72. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1:1982;1142-1147.
73. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmiass. N Engl J Med. 329:1993;445-451.
74. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmiass. N Engl J Med. 329:1993;452-458.
75. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol. 72:1993;280-287.
76. A randomized trial of propranolol in patients with acute myocardial infarction 1. Mortality results . JAMA. 247:1982;1707-1714.
77. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
78. Metoprolol in acute myocardial infarction (MIAMI) a randomized placebo-controlled international trial . Eur Heart J. 6:1985;199-226.
79. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 260:1988;2088-2093.
80. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure. Circulation. 92:1995;1499-1506.
81. Kennedy HL, Goldstein S, Barker AH, Brooks MM, Huther M, Beanlands DS, Bigger JT, Bergstrand R. β-blocker therapy and congestive heart failure in the Cardiac Arrhythmia Suppression Trial (CAST). (Abstr.). J Am Coll Cardiol. 21:1993;378A.
82. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 68:1991;1025-1031.
83. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Preliminary mortality results from the Survival with Oral d-sotalol (SWORD) Trial. (Abstr.) J Am Coll Cardiol. 25:1995;15A.
84. Reiffel JA, Hahn E, Hartz V, Reiter MJ. Sotalol for ventricular tachyarrhythmiass β-blocker and class III contributions and relative efficacy versus class I drugs after prior drug failure . Am J Cardiol. 79:1997;1048-1053.
85. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmiass Basel Antiarrhythmic Study of Infarct Survival (BASIS) . J Am Coll Cardiol. 16:1990;1711-1718.
86. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Mitek J, Paczkowska B, Sczaniecka O, Yusuf S. Effect of amiodarone on mortality after myocardial infarction a double-blind, placebo-controlled, pilot study . J Am Coll Cardiol. 20:1992;1056-1062.
87. Pfisterer M, Kiowski W, Burckhardt D, Follath F, Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmiass after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol. 69:1992;1399-1402.
88. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
89. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations CAMIAT . Lancet. 349:1997;675-682.
90. Anderson JL. Effectiveness of sotalol for therapy of complex ventricular arrhythmiass and comparisons with placebo and class I antiarrhythmic drugs. Am J Cardiol. 65:1990;37A-42A.
91. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 333:1995;77-82.
92. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
93. Weaver WD, Cobb LA, Hallstrom AP. Ambulatory arrhythmiass in resuscitated victims of cardiac arrest. Circulation. 66:1982;212-218.
94. Flaker GC, Alpert MA, Webel RR, Ruder MA, Sanfelippo JF, Tsutakawa RK. Amiodarone and sustained ventricular arrhythmiass statistical evidence of drug effectiveness . Am Heart J. 110:1985;371-376.
95. Kay GN, Pryor DB, Lee KL, Harrell FE, Pressley JC, Gilbert MR, German LD. Comparison of survival of amiodarone-treated patients with coronary artery disease and malignant ventricular arrhythmiass with that of a control group with coronary artery disease. J Am Coll Cardiol. 9:1987;877-881.
96. Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 305:1981;539-545.
97. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmiass . Circulation. 68:1983;88-94.
98. Fisher JD, Brodman RF, Kim SG, Ferrick KJ, Roth JA. VT/VF 60/60 protection . PACE. 13:1990;218-222.
99. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, Goldberg H, Scheinman MM. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 13:1989;442-449.
100. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C, Zipes DP. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J. 125:1993;109-120.
101. Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmiass. J Am Coll Cardiol 12:1568-1572; 1998.
102. Kehoe RF, Zheutlin TA, Dunnington CS, Mattioni TA, Yu G, Spangenberg RB. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmiass. Am J Cardiol. 65:1990;58A-64A.
103. Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmiass. J Am Coll Cardiol. 13:1989;145-152.
104. Kus T, Campa MA, Nadeau R, Dubuc M, Kaltenbrunner W, Shenasa M. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am Heart J. 123:1992;82-89.
105. Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmiass. Eur Heart J. 10:1989;685-694.
106. Kovoor P, Yung A, Byth K, Eipper VE, Cousins KL, Uther JB, Cooper MJ, Ross DL. Comparison of sotalol, amiodarone and automatic implantable cardioverter defibrillator for treatment of documented spontaneous sustained ventricular tachyarrhythmiass secondary to coronary artery disease. (Abstr.) Circulation. 92:1995;I-782.
107. Wellens HJ, Schuilenburg RM, Durrer D. Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation. 46:1972;216-226.
108. Wellens HJJ, Bar FWHM, Lie KI, Duren DR, Dohmen HJ. Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. Am J Cardiol. 40:1977;579-585.
109. Vandepol CJ, Farshidi A, Spielman SR, Greenspan AM, Horowitz LN, Josephson ME. Incidence and clinical significance of induced ventricular tachycardia. Am J Cardiol. 45:1980;725-731.
110. Horowitz LN, Josephson ME, Kastor JA. Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmias. Prog Cardiovasc Dis. 23:1980;81-97.
111. Mason JW, Winkle RA. Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med. 303:1980;1073-1077.
112. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AM. Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimes. Circulation. 58:1978;986-997.
113. Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, Ruskin JN. Out-of-hospital cardiac arrest use of electrophysiologic testing in the prediction of long-term outcome . N Engl J Med. 318:1988;19-24.
114. Troup PJ. Programmed stimulation-guided therapy compared with implantable cardioverter defibrillator device therapy in the treatment of ventricular tachyarrhythmiass. PACE. 14:1991;267-272.
115. Bigger JT Jr, Reiffel JA, Livelli FD Jr, Wang PJ. Sensitivity, specificity, and reproducibility of programmed ventricular stimulation. Circulation. 73:(suppl II):1986;II73-II78.
116. Brugada P, Green M, Abdollah H, Wellens HJJ. Significance of ventricular arrhythmiass initiated by programmed ventricular stimulation the importance of the type of ventricular arrhythmias induced and the number of premature stimuli required . Circulation. 69:1984;87-92.
117. Josephson ME. Recurrent ventricular tachycardia. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2nd ed. Malvern, Pa: Lea & Febiger, 1992:417-615.
118. Myerberg RJ, Sung RJ, Conde CA, Mallon SM, Castellanos A. Intracardiac electrophysiologic studies in patients resuscitated from unexpected cardiac arrest outside the hospital (Abstr.) . Am J Cardiol. 39:1997;275.
119. Roy D, Waxman HL, Kienzle MC, Buxton AE, Marchlinski FE, Josephson ME. Clinical characteristics and long-term follow-up in 119 survivors of out-of-hospital cardiac arrest relation to inducibility at electrophysiologic testing . Am J Cardiol. 52:1983;969-974.
120. Morady F, Scheinman MM, Hess DS, Sung RJ, Shen E, Shapiro W. Electrophysiologic testing in the management of survivors of out-of-hospital cardiac arrest. Am J Cardiol. 51:1983;85-89.
121. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J. 124:1992;1035-1045.
122. De Paola AA, Horowitz LN, Morganroth J, Senior S, Spielman SR, Greenspan AM, Kay HR. Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol. 9:1987;163-168.
123. Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmias treated with antiarrhythmic drugs. Am J Cardiol. 50:1982;437-443.
124. Lampert S, Lown B, Graboys TB, Podrid PJ, Blatt CM. Determinants of survival in patients with malignant ventricular arrhythmias associated with coronary artery disease. Am J Cardiol. 61:1988;791-797.
125. Chua W, Roth H, Summers C, Zheutlin TA, Kehoe RF. Programmed stimulation versus ambulatory monitoring for therapy of malignant arrhythmiass (Abstr.) . Circulation. 68:1983;III-55.
126. Platia EV, Reid PR. Comparison of programmed electrical stimulation and ambulatory electrocardiographic (Holter) monitoring in the management of ventricular tachycardia and ventricular fibrillation. J Am Coll Cardiol. 4:1984;493-500.
127. Skale BT, Miles WM, Heger JJ, Zipes DP, Prystowsky EN. Survivors of cardiac arrest prevention of recurrence by drug therapy as predicted by electrophysiologic testing or electrocardiographic monitoring . Am J Cardiol. 57:1986;113-119.
128. Mitchell LB, Duff HJ, Manyari DE, Wyse DG. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med. 317:1987;1681-1687.
129. Reiter MJ, Mann DE, Reiffel JE, Hahn E, Hartz V. Significance and incidence of concordance of drug efficacy predictions by Holter monitoring and electrophysiologic study in the ESVEM trial. Circulation. 91:1995;1988-1995.
130. Antz M, Cappato R, Kuck KH. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. J Cardiovasc Pharmacol. 26:1995;627-635.
131. Steinbeck G, Andresen D, Bach P, Haberl R, Oeff M, Hoffmann E, von Leitner E. A comparison of electrophysiologically guided antiarrhythmic drug therapy with β-blocker therapy in patients with symptomatic, sustained ventricular arrhythmiass. N Engl J Med. 327:1992;987-992.
132. Antiarrhythmic versus implantable defibrillators (AVID) - rationale, design, and methods. Am J Cardiol. 75:1995;470-475.
133. Reiffel JA. Prolonging survival by reducing arrhythmic death pharmacologic therapy of ventricular tachycardia and fibrillation . Am J Cardiol. 80:(suppl):1997;45G-55G.
134. Haverkamp W, Eckardt L, Borggrefe M, Breithardt G. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Am J Cardiol. 80(suppl):1997;67G-73G.
135. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D. Canadian Implantable Defibrillator Study (CIDS) study design and organization . Am J Cardiol. 72:1993;103F-108F.
136. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 127:1994;1139-1144.
137. Kuck KH. The Cardiac Arrest Study Hamburg (CASH) Interim report . Rev Eur Tech Biomed. 12:1990;110.